Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: rituximab

Case Report: GPA Presenting as Neuropathy

Ann George, MD, Azin Azarfar, MD, Shazia Bég, MD, & Maria Farooq, MD  |  December 16, 2021

Granulomatosis with polyangiitis (GPA), is a type of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) that affects small- to medium-sized vessels.1 It can occur equally in both men and women, with a reported mean age at onset of 55 years.2 The classical presentation of GPA includes upper respiratory tract (i.e., chronic sinusitis, serous otitis and…

Filed under:ConditionsVasculitis Tagged with:AAVAAV FocusRheumANCA-Associated Vasculitiscase reportgranulomatosis with polyangiitisneuropathy

Alpha Tauri 3D Graphics / shutterstock.com

Rheumatic Complications from Immune Checkpoint Inhibitors

Nilasha Ghosh, MD, MS, & Anne R. Bass, MD  |  December 16, 2021

Immune checkpoint inhibitors (ICIs), such as anti-programmed cell-death 1/programmed death-ligand 1 (anti-PD-1/PD-L1) or anti-CTL-associated protein (anti-CTLA-4), have dramatically changed the treatment of advanced cancers over the past decade. ICIs block T cell inhibition, thus increasing the anti-tumor immune response. ICIs are used not only for metastatic cancer, but also as adjuvant treatment for some stage…

Filed under:Conditions Tagged with:immune checkpoint inhibitor (ICI)immune-related adverse events

Therapeutics for COVID-19: An update from ACR Convergence 2021

Lara C. Pullen, PhD  |  December 10, 2021

ACR CONVERGENCE 2021—Rheumatology patients who test positive for COVID-19 would benefit from early use of monoclonal antibodies, said Luis Ostrosky-Zeichner, MD, chief of the Division of Infectious Diseases, McGovern Medical School, University of Texas Health Science Center (UTHealth), Houston, in a session about effective treatment options for COVID-19. Acknowledging that the SARS-CoV-2 virus has already…

Filed under:ACR ConvergenceBiologics/DMARDsMeeting Reports Tagged with:ACR Convergence 2021COVID-19

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Jeffrey Curtis, MD, MS, MPH  |  December 7, 2021

ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…

Filed under:ACR ConvergenceConditionsMeeting ReportsResearch RheumRheumatoid Arthritis Tagged with:ACR Convergence 2021ACR Convergence 2021 – RA

Good Flow: 2021 Updates in Vasculitis

Jason Liebowitz, MD, FACR  |  December 6, 2021

During the ACR Convergence 2021 annual Review Course, Peter Merkel, MD, MPH, provided recent updates on vasculitis.

Filed under:ACR ConvergenceClinical Criteria/GuidelinesConditionsMeeting ReportsVasculitis Tagged with:ACR Convergence 2021

Management of Inflammatory Myositis: Options for Refractory Disease & New Therapies Discussed

Mary Beth Nierengarten  |  December 2, 2021

Options to escalate treatment for refractory inflammatory myositis and new therapies in the pipeline are discussed.

Filed under:ACR ConvergenceConditionsMeeting ReportsMyositis Tagged with:ACR Convergence 2021myositispatient care

From Strength to Strength: Idiopathic Inflammatory Myopathy Diagnosis & Management

Jason Liebowitz, MD, FACR  |  December 2, 2021

During the ACR Convergence 2021 Review Course, Rohit Aggarwal, MD, MS, provided an update on idiopathic inflammatory myopathy.

Filed under:ACR ConvergenceConditionsMeeting ReportsMyositisOther Rheumatic Conditions Tagged with:ACR Convergence 2021myositis

The State of Clinical Science for Pediatric Rheumatology in 2021

Elizabeth Sloan, MD  |  December 2, 2021

ACR Convergence 2021—The Pediatric Rheumatology Year in Review began with a fascinating talk by Mara Becker, MD, MSCE, a professor of Pediatrics and vice chair of faculty at Duke University School of Medicine, Durham, N.C. Dr. Becker began by describing her search strategy to select high-yield clinical science publications in pediatric rheumatology from the past…

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2021ClinicalCOVID-19JIAMultisystem Inflammatory Syndrome in Children (MIS-C)PediatricPediatric Rheumatologypolyarticular juvenile idiopathic arthritis (JIA)

Experts Discuss Blood Disorders Commonly Seen in Lupus Patients

Samantha C. Shapiro, MD  |  December 2, 2021

ACR CONVERGENCE 2021—Hematologic abnormalities are common in systemic lupus erythematosus (SLE), whether due to SLE itself or something else. As rheumatology professionals, we are routinely challenged by the management of cytopenias in our SLE patients. At the ACR’s annual meeting in 2021, two hematologists shared expert advice regarding common hematologic manifestations of SLE. Michael B….

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLEanemiaAntiphospholipid Antibody Syndrome (APS)immune thrombocytopeniamacrophage activation syndromeneutropeniathrombocytopenia

The Many Facets of COVID-19: Experts Address Basic & Clinical Research Concepts in the COVID-19 Era

Jason Liebowitz, MD, FACR  |  November 23, 2021

New concepts in autoimmunity & immunology are being discovered daily in research being conducted to understand the SARS-CoV-2 virus and its implications for rheumatology & all fields of medicine. Here are some insights shared by experts during day 1 of the Basic and Clinical Research Conference.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2021COVID-19Multisystem Inflammatory Syndrome in Children (MIS-C)U.S. Food and Drug Administration (FDA)vaccine hesitancy

  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 45
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences